Table 1 Patient characteristics
Low-level TUBB3 expression | High-level TUBB3 expression | P | |
|---|---|---|---|
H-score 1-3 | H-score 4-6 | ||
Age | |||
< 56 | 32 (44.4) | 40 (55.6) | 0.105 |
≥ 56 | 37 (50.0) | 37 (50.0) | |
Sex | |||
Male | 49 (47.1) | 55 (52.9) | 1 |
Female | 20 (47.6) | 22 (52.4) | |
Location | |||
GEJ-cardia | 9 (56.3) | 7 (43.8) | 0.8 |
Body | 42 (45.7) | 50 (54.3) | |
Antrum | 18 (47.4) | 20 (52.6) | |
Differentiation | |||
Well, moderately | 15 (41.7) | 21 (58.3) | 0.45 |
Poorly, signet ring cell | 54 (49.1) | 56 (509) | |
Lauren classification | |||
Intestinal | 41 (47.7) | 45 (52.3) | 0.211 |
Diffuse | 17( 39.5) | 26 (60.5) | |
Mixed | 11 (64.7) | 6 (35.3) | |
Disease status | |||
Initial metastasis | 41 (45.6) | 49 (54.4) | 0.614 |
Recurrence after curative resection | 28 (50.0) | 28 (50.0) | |
Metastatic site | |||
Liver | |||
Yes | 20 (48.8) | 21 (51.2) | 0.855 |
No | 49 (46.7) | 56 (53.3) | |
Peritoneum | |||
Yes | 35 (53.0) | 31 (47.0) | 0.245 |
No | 34 (42.5) | 46 (57.5) | |
Bone | |||
Yes | 5 (50.0) | 5 (50.0) | 1 |
No | 64 (47.1) | 72 (52.9) | |
Chemotherapy response | |||
CR + PR | 34 (54.8) | 28 (45.2) | 0.133 |
SD + PD | 35 (41.7) | 49 (58.3) | |
Chemotherapeutic regimen | |||
Paclitaxel and cisplatin | 58 (44.3) | 73 (55.7) | 0.053 |
Docetaxel and cisplatin | 11 (73.3) | 4 (26.7) | |
No. of involved organs | |||
1 | 41 (41.8) | 57 (58.2) | 0.107 |
2 | 25 (61.0) | 16 (39.0) | |
≥ 3 | 3 (42.9) | 4 (57.1) | |
ERCC1 H-score | |||
1-3 | 36 (52.9) | 32 (47.1) | 0.245 |
4-6 | 33 (42.3) | 45 (57.7) |